Screener
Rigel Pharmaceuticals RIGL Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total costs and expenses | 46,933 | 40,560 |
| Income from operations | 11,885 | 12,773 |
| Interest income | 1,205 | 591 |
| Interest expense | (1,433) | (1,853) |
| Income before income taxes | 11,657 | 11,511 |
| Provision for income taxes | 3,003 | 65 |
| Net income | $8,654 | $11,446 |
| Net income per share |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's interest expense?
- Rigel Pharmaceuticals (RIGL) reported interest expense of $1.43M in Q1 2026.
- How has Rigel Pharmaceuticals's interest expense changed year-over-year?
- Rigel Pharmaceuticals's interest expense decreased by 22.7% year-over-year, from $1.85M to $1.43M.
- What is the long-term trend for Rigel Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's interest expense has grown at a 10.8% compound annual growth rate (CAGR), from $4.86M to $7.32M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Rigel Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude